{Reference Type}: Journal Article
{Title}: Toward a comprehensive solution for treating solid tumors using T-cell receptor therapy: A review.
{Author}: Ma P;Jiang Y;Zhao G;Wang W;Xing S;Tang Q;Miao H;Fang H;Sun C;Fang Y;Jiang N;Huang H;Wang S;Xie X;Li N;
{Journal}: Eur J Cancer
{Volume}: 209
{Issue}: 0
{Year}: 2024 Sep 10
{Factor}: 10.002
{DOI}: 10.1016/j.ejca.2024.114224
{Abstract}: T-cell receptor therapy (TCR-T) has demonstrated efficacy, durability, and safety advantages in certain solid tumors (such as human papillomavirus-related tumors, synovial sarcoma, and melanoma). This study aimed to provide careful considerations for developing TCR-T for solid tumors. Therefore, in this review, we have summarized the current clinical application, advantage of TCR-T modalities and explored efficacy/safety-related parameters, particularly avidity, pharmacokinetics/pharmacodynamics, and indications, for solid tumors. Furthermore, we have investigated critical factors related to avidity, including antigen selection, T-cell receptor acquisition, optimization, and co-receptor engagement. Moreover, we have re-examined the expression of tumor antigens for a potentially higher coverage rate of solid tumors based on the current RNA-seq datasets. Finally, we have discussed the current limitations and future directions of TCR-Ts.